Behzad Aghazadeh
Managing Team @ venBio Partners
Behzad Aghazadeh is a Series B investor at venBio Partners focused on Therapeutics and Biotechnology. Behzad Aghazadeh - Managing Team @ venBio Partners
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Behzad Aghazadeh invests in
Stages Behzad Aghazadeh invests in
Countries Behzad Aghazadeh invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Life Science 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
Country
- Switzerland 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scribe Therapeutics
|
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. Italso a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA. | $100M / Series B / Mar 31, 2021 | |
|
Scribe Therapeutics
|
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. Italso a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA. | $100M / Series B / Mar 31, 2021 | |
Monte Rosa Therapeutics
|
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. | $95M / Series C / Mar 12, 2021 |
Co-Investors
About venBio Partners
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
venBio Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Behzad Aghazadeh
Managing Team
|
|||
Corey Goodman
Managing Partner
|
|||
Richard Gaster
Managing Partner
|
|||
Robert Adelman
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Behzad Aghazadeh invest in?
Behzad Aghazadeh invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Behzad Aghazadeh?
Public channels for Behzad Aghazadeh include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Behzad Aghazadeh last invest?
The most recent investment recorded for Behzad Aghazadeh closed in Mar 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
